No, do not start a Cardizem (diltiazem) drip in a patient with STEMI.
Cardizem is explicitly contraindicated in patients with acute myocardial infarction and pulmonary congestion documented by x-ray on admission 1. This is a clear FDA black-and-white contraindication that takes precedence over any other consideration.
Key Contraindications and Warnings
The FDA drug label for intravenous Cardizem lists the following absolute contraindications 1:
- Acute myocardial infarction with pulmonary congestion on chest x-ray
- Hypotension (systolic BP < 90 mmHg)
- Sick sinus syndrome (without pacemaker)
- Second- or third-degree AV block (without pacemaker)
Additionally, diltiazem carries significant warnings for 1:
- Congestive heart failure: Diltiazem has negative inotropic effects and can worsen heart failure
- Cardiac conduction abnormalities: Can cause second- or third-degree AV block (0.48% incidence)
- Hypotension: Can cause symptomatic blood pressure drops
Clinical Context in STEMI
The 2017 ESC and 2013 ACCF/AHA STEMI guidelines make no mention of calcium channel blockers like diltiazem as part of acute STEMI management 223. The cornerstone pharmacological therapies are:
- Anticoagulants (unfractionated heparin, enoxaparin, or bivalirudin)
- Dual antiplatelet therapy (aspirin plus prasugrel/ticagrelor)
- Beta-blockers (oral, initiated within 24 hours if no contraindications)
- ACE inhibitors (within 24 hours for anterior MI, heart failure, or EF ≤ 0.40)
Beta-blockers, not calcium channel blockers, are the Class I recommendation for rate control and anti-ischemic therapy in STEMI 3.
Research Evidence Limitations
While some older studies from the 1980s examined intravenous diltiazem in acute MI 456, these are outdated and preceded modern reperfusion strategies. More recent studies examined intracoronary (not intravenous drip) diltiazem administration during PCI to prevent no-reflow 78, which is a completely different clinical scenario than starting a systemic diltiazem infusion.
Critical Pitfalls to Avoid
- Do not confuse intracoronary diltiazem during PCI with systemic IV infusion: Intracoronary administration during catheterization for no-reflow prevention is distinct from starting a drip
- Check for pulmonary congestion: If present on chest x-ray, this is an absolute contraindication
- Assess hemodynamics carefully: Many STEMI patients have borderline blood pressure or are at risk for cardiogenic shock
- Monitor for conduction abnormalities: Diltiazem can precipitate high-grade AV block, especially in inferior/posterior MI
- Consider beta-blockers first: These are guideline-recommended and have mortality benefit in STEMI
When Diltiazem Might Be Considered (Not in Acute STEMI)
Diltiazem may have a role in stable coronary disease or hypertension with ischemia 9, but not in the acute STEMI setting. If rate control is needed in STEMI and beta-blockers are contraindicated, consider alternative strategies rather than calcium channel blockers.